Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Prof Franco Muggia talks to ecancertv about the latest in intraperitoneal therapy. Giving cisplatin direct to the abdomen rather than intravenously. Talking at the 2011 Chemotherapy Foundation Symposium, New York.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Choosing the right patients for transplant
ESMO 2024: Latest in EGFR mutated NSCLC
Some advanced epithelial ovarian cancer patients can avoid a lymphadenectomy without impacting survival outcomes
Gynaecological cancer: New targets and immunotherapy developments
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients